Opinion|Videos|November 15, 2024
The Role of Dermatologists in Treating CSU
Key Takeaways
- CSU management involves general practitioners, allergists, and dermatologists, with varying patient distribution among these specialists.
- Dermatologists may provide more specialized care for CSU due to their expertise in skin conditions.
Panelists discuss how, given that approximately 49% of patients with chronic spontaneous urticaria (CSU) consult general practitioners, while only approximately 19% see dermatologists, there is a compelling case for more patients to be referred to dermatologists, as CSU is an internally driven disease that may benefit from specialized expertise.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Approximately 49% of patients with CSU see a general practitioner, approximately 30% see an allergist, and approximately 19% see a dermatologist. Given that CSU is an internally driven disease, should more patients be seeing dermatologists?
Advertisement
Related to this article
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Bepirovirsen for Chronic Hepatitis B
2
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
5